Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 76, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.intimp.2019.105877
Keywords
Acute respiratory distress syndrome; Resident alveolar macrophages; Resolvin D1; CXCL2
Categories
Funding
- National Natural Science Foundation of China [81571862, 81270132, 81870065]
- Natural Science Foundation of Zhejiang Province [LY18H010005, LQ15H010002]
- Wenzhou Science and Technology Bureau Project [Y20170034]
Ask authors/readers for more resources
Acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) are life-threatening critical syndromes characterized by the infiltration of a large number of inflammatory cells that lead to an excessive inflammatory response. Resolvin D1 (RvD1), an endogenous lipid mediator, is believed to have anti-inflammatory and proresolving effects. In the present study, we examined the impact of RvD1 on the pulmonary inflammatory response, neutrophil influx, and lung damage in a murine model of lipopolysaccharide (LPS)-induced ALI. Treatment with RvD1 protected mice against LPS-induced ALI, and compared to untreated mice, RvD1-treated mice exhibited significantly ameliorated lung pathological changes, decreased tumor necrosis factor-alpha (TNF-alpha) concentrations and attenuated neutrophil infiltration. In addition, treatment with RvD1 attenuated LPS-induced neutrophil infiltration via the downregulation of CXCL2 expression on resident alveolar macrophages. Finally, BOC-2, which inhibits the RvD1 receptor lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2), reversed the protective effects of RvD1. These data demonstrate that RvD1 ameliorates LPS-induced ALI via the suppression of neutrophil infiltration by an ALX/FPR2-dependent reduction in CXCL2 expression on resident alveolar macrophages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available